TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06689371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (Dry Needling)
Description: The patient will receive dry needling on suboccipital, upper trapezius and SCM muscles with conventional therapy 3 sessions per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B (Dry cupping)
Description: Patients will receive dry cupping on suboccipital, upper trapezius and SCM muscles weeks with conventional therapy 3 sessions per week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C (control)
Description: will receive standard exercise three sessions per week for four weeks. This standard regimen consists of the same exercises as group A and B.
Study: NCT06552130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spiroergometer test with intranasal insulin spray
Description: Participants will undergo a 60 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spiroergometer test with intranasal placebo spray
Description: Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
Study: NCT06695676

Intervention type: DIAGNOSTIC_TEST
Intervention: Global Longitudinal Strain
Description: Global longitudinal strain measurement is a more objective method to determine left ventricular systolic function than traditional eyeballing method. It helps to detect and quantify subtle changes even so it is an emerging method to evaluate the cardiotoxicity of chemotherapeutic drugs. It is planned to compare each selected patient's GLS measurement before starting to use lurasidone and after six months of using it. Hereby our aim is to find if lurasidone has any effect on left ventricular systolic function.
Study: NCT06687473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-based susceptibility-guided treatment
Description: The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori.~A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
Study: NCT05995665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoGLOVE with Trigno Biofeedback (EMG sensors)
Description: The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVETM with Trigno Biofeedback (EMG sensors) training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day. A total of 15 sessions (5 session per week for a total of 3 weeks) of a minimum of 30 mins. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded Repetitive Arm Supplementary Program (GRASP)
Description: Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
Study: NCT05202171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Stabilization Exercise
Description: Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
Study: NCT05370144

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
Study: NCT06294431

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 1.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 2
Description: Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 2.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 3
Description: Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 3.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 3.2 Usage
Description: Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 4
Description: Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 4.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
Study: NCT04628975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transillumination dispositif
Description: infrared light
Study: NCT04816201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
Study: NCT05016284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JW-100
Description: Cosmetic CBD cream (JW-100)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eucrisa
Description: Topical EUCRISA®, Pfizer
Study: NCT06130306

Intervention type: PROCEDURE
Intervention: electrical pudendal nerve stimulation
Description: The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 45 minutes targeted the pudendal nerve, thrice weekly for a minimum of 8 weeks. The treatment plan remains ongoing until the patient opts to discontinue voluntarily.

Intervention type: PROCEDURE
Intervention: pelvic floor muscle training combined with transanal electrical stimulation
Description: Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system \[AM1000B; Shenzhen Creative Industry Co. Ltd, China\]) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB 4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible to get a PFM contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients also conducted 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks. If the patient is willing, the treatment plan can continue until the patient voluntarily decides to stop.
Study: NCT05832021

Intervention type: PROCEDURE
Intervention: Open reduction and internal fixation (under WALANT)
Description: Open reduction and internal fixation with volar Henry approach under WALANT.

Intervention type: PROCEDURE
Intervention: Open reduction and internal fixation (under peripheral nerve block)
Description: Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
Study: NCT04150549

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbial Transplants
Description: Healthy donor stool will be processed and placed into capsules.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbial Transplants
Description: Participants stool will be processed and placed into capsules.
Study: NCT05343481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human immunoglobulin G4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human immunoglobulin G4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human immunoglobulin G4 monoclonal antibody
Study: NCT05764720

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily Adaptive External Beam Radiation Therapy
Description: Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Study: NCT05357807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard RYGB
Description: Roux-en-Y Gastric bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pouch RYGB
Description: Roux-en-Y gastric bypass with an extended pouch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Banded extended pouch RYGB
Description: Roux-en-Y gastric bypass with a banded extended pouch
Study: NCT05547802

Intervention type: BIOLOGICAL
Intervention: BBIBP-CorV and/or BNT162b2 vaccine
Description: Booster immunization was carried out at least 4 months after the first two doses of basic immunization.

Intervention type: BIOLOGICAL
Intervention: BBIBP-CorV and/or BNT162b2 vaccine
Description: Booster immunization was carried out at least 4 months after the first two doses of basic immunization.
Study: NCT06492941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for Injection (Albumin bound)
Description: Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was human blood albumin without the active ingredient docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
Study: NCT06229886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of positive-end-expiratory pressure
Description: Application of PEEP on mechanically ventilated pediatric patients. Point-of-care-ultrasound performed after each PEEP application.
Study: NCT05012423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC0509
Description: ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC0509
Description: ECC0509 1 mg and 10 mg capsules
Study: NCT04752540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olorofim
Description: single oral dose
Study: NCT05274776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS calculator
Description: For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
Study: NCT06097195

Intervention type: DEVICE
Group type: OTHER
Intervention: BioEP
Description: When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
Study: NCT05711667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Given PO or IV
Study: NCT05795465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn-1124
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn-1124
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn-1124
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT05975567

Intervention type: OTHER
Intervention: Three-dimensional imaging of the collected cardiac specimens
Description: The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
Study: NCT06347627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1 (I x S x S x F)
Description: Experimental message: Individual x Safety x Storytelling x Factual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2 (O x S x S x F)
Description: Experimental message: Organization x Safety x Storytelling x Factual
Study: NCT05857137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TMS
Description: Continuous theta burst stimulation (cTBS) will be administered over the left inferior parietal lobule for approximately 3 minutes at 120% of the resting motor threshold.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TMS
Description: Placebo TMS will be applied over the left inferior parietal lobule for approximately 3 minutes.
Study: NCT04482855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser
Description: Low-level laser therapy
Study: NCT06436547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subiculum-DBS ON
Description: The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are biliteral subiculum.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
Study: NCT05975567

Intervention type: OTHER
Intervention: Three-dimensional imaging of the collected cardiac specimens
Description: The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.

Intervention type: OTHER
Intervention: Three-dimensional imaging of the collected cardiac specimens
Description: The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
Study: NCT03787290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: participants will receive a single subcutaneous injection of tocilizumab (162 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: participants will receive a single subcutaneous injection of saline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Hyperthermia
Description: subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-Body Hyperthermia
Description: subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
Study: NCT05419674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT03886675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 flushing
Description: As above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline flushing
Description: As above
Study: NCT05050370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief messaging and personalized support
Description: Patients will receive (i) a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise (including breathing, balance, aerobic, strength, stretching exercises), cancer-related care information and support.
Study: NCT05205486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 3gm for Injection USP and Dextrose Injection USP
Description: Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing \>/= 120 kg